CEO Yuval Cohen was paid $3,750,125 in fiscal year 2025, ↓ down 11.7% from fiscal year 2024 (SEC filing 0001193125-26-140363 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$3,750,125 ↓ Yuval Cohen total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | 92.82% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
CRBP's next annual pay disclosure, estimated April 3, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Yuval Cohen | $646,566 | $373,682 | $666,699 | $2,039,294 | $0 | $0 | $23,884 | $3,750,125 |
| Chief Executive Officer and Director | ||||||||
| Dominic Smethurst | 519,313 | 168,078 | 266,288 | 812,866 | 0 | 0 | 33,597 | 1,800,142 |
| Chief Medical Officer | ||||||||
| Sean Moran | 481,137 | 185,382 | 269,225 | 824,453 | 0 | 0 | 29,226 | 1,789,423 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Yuval Cohen | $3,750,125 | $4,245,438 | $1,137,622 | ↓ −495,313 |
| Dominic Smethurst | 1,800,142 | 2,892,972 | — | ↓ −1,092,830 |
| Sean Moran | 1,789,423 | 2,429,505 | 717,256 | ↓ −640,082 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Corbus Pharmaceuticals Holdings's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CRBP reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses CRBP in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CRBP in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Alan Holmer | Former director (through FY2025) | $200,618 |
| Anne Altmeyer | Independent Director | $193,846 |
| John Jenkins | Independent Director | $208,200 |
| Peter Salzmann | Former director (through FY2025) | $16,690 |
| Rachelle Jacques | Chair of the Board | $215,782 |
| Winston Kung | Independent Director | $203,200 |
| Yong Ben | Independent Director | $195,700 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Brent Pfeiffenberger | Director | 2026-05-19 | A | 7,500 | $0 | $0 | RSU | Form 4 ↗ |
| Anne Altmeyer | Director | 2026-05-19 | A | 3,800 | 0 | 0 | RSU | Form 4 ↗ |
| John Jenkins | Director | 2026-05-19 | A | 12,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rachelle Jacques | Director | 2026-05-19 | A | 3,800 | 0 | 0 | RSU | Form 4 ↗ |
| Yong Ben | Director | 2026-05-19 | A | 12,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anne Altmeyer | Director | 2026-05-19 | A | 12,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brent Pfeiffenberger | Director | 2026-05-19 | A | 24,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Jenkins | Director | 2026-05-19 | A | 3,800 | 0 | 0 | RSU | Form 4 ↗ |
| Rachelle Jacques | Director | 2026-05-19 | A | 12,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Yong Ben | Director | 2026-05-19 | A | 3,800 | 0 | 0 | RSU | Form 4 ↗ |
| Winston Kung | Director | 2026-05-19 | A | 12,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Winston Kung | Director | 2026-05-19 | A | 3,800 | 0 | 0 | RSU | Form 4 ↗ |
| Nishant C. Saxena | Chief Business Officer | 2026-05-21 | A | 192,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nishant C. Saxena | Chief Business Officer | 2026-05-21 | A | 58,300 | 0 | 0 | Common | Form 4 ↗ |
| Nishant C. Saxena | Chief Business Officer | 2026-06-02 | A | 4,500 | 7 | 32,999 | Common | Form 4 ↗ |
| Nishant C. Saxena | Chief Business Officer | 2026-06-03 | A | 9,000 | 8 | 68,220 | Common | Form 4 ↗ |
| Winston Kung | Director | 2026-06-10 | D | 2,026 | 8 | 16,033 | Common | Form 4 ↗ |
| John Jenkins | Director | 2026-06-10 | D | 4,800 | 8 | 37,986 | Common | Form 4 ↗ |
| Anne Altmeyer | Director | 2026-06-10 | D | 2,412 | 8 | 19,088 | Common | Form 4 ↗ |
| Yuval Cohen | Director | 2026-08-07 | D | 17,000 | 10 | 171,396 | Common | Form 4 ↗ |
| Sean Moran | Chief Financial Officer | 2026-08-07 | D | 12,000 | 10 | 120,971 | Common | Form 4 ↗ |
| Nishant C. Saxena | Chief Business Officer | 2026-08-11 | A | 2,600 | 10 | 25,036 | Common | Form 4 ↗ |
| Leonardo Viana Nicacio | Chief Medical Officer | 2026-08-16 | A | 191,676 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonardo Viana Nicacio | Chief Medical Officer | 2026-08-16 | A | 58,333 | 0 | 0 | Common | Form 4 ↗ |
| Yong Ben | Director | 2026-09-14 | D | 2,000 | 8 | 15,683 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Sean Moran | Option | — | — | — | — | — | $824,453 |
| Dominic Smethurst | Option | — | — | — | — | — | 812,866 |
| Yuval Cohen | RSU | — | — | — | — | — | 666,699 |
| Sean Moran | RSU | — | — | — | — | — | 269,225 |
| Yuval Cohen | Option | — | — | — | — | — | 2,039,294 |
| Dominic Smethurst | RSU | — | — | — | — | — | 266,288 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Sean Moran | $269,225 | $0 | $824,453 | 0.0% |
| Dominic Smethurst | 266,288 | 0 | 812,866 | 0.0% |
| Yuval Cohen | 666,699 | 0 | 2,039,294 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Sean Moran | PSU | 30,132 | — | $245,274 |
| Sean Moran | Option | 748 | 14.1 | — |
| Yuval Cohen | PSU | 55,461 | — | 451,453 |
| Dominic Smethurst | Option | 91,200 | 9.79 | — |
| Dominic Smethurst | PSU | 37,500 | — | 305,250 |
| Sean Moran | Option | 92,500 | 9.79 | — |
| Sean Moran | Option | 9,087 | 4.26 | — |
| Yuval Cohen | Option | 2,070 | 14.1 | — |
| Yuval Cohen | Option | 228,800 | 9.79 | — |
| Yuval Cohen | PSU | 68,100 | — | 554,334 |
| Sean Moran | PSU | 27,500 | — | 223,850 |
| Dominic Smethurst | PSU | 27,200 | — | 221,408 |
| Yuval Cohen | Option | 19,343 | 4.26 | — |
| Yuval Cohen | Option | 40,055 | 23 | — |
| Sean Moran | Option | 21,762 | 23 | — |
| Dominic Smethurst | Option | 27,084 | 26.07 | — |
The Company's compensation program is designed to attract and retain highly skilled personnel in the competitive life sciences industry. Executive compensation consists of base salary, annual discretionary bonus (targeted at 60% of salary for CEO, 40% for other NEOs), and equity awards (stock options and RSUs), with the goal of aligning executive interests with stockholder value creation and rewarding individual and company performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia, Inc. |
| Clawback policy | true |
| Anti-hedging | True |
| Anti-pledging | False |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-13 | 9,325,932 | 721,442 | 26,696 | 92.82% | Passed |
| 2025 | 2025-05-15 | 6,519,904 | 215,784 | 11,102 | 96.8% | Passed |
| 2024 | 2024-05-16 | 6,593,949 | 44,363 | 9,862 | 99.33% | Passed |
| 2023 | 2023-05-18 | 244,160 | 60,487 | 9,370 | 80.15% | Passed |
| 2021 | 2021-06-17 | 36,346,860 | 4,599,776 | 634,982 | 88.77% | Passed |
| 2020 | 2020-05-20 | 18,992,387 | 2,303,630 | 323,179 | 89.18% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-13 | 92.82%a |
| 2025 | 2025-05-15 | 96.8%b |
| 2024 | 2024-05-16 | 99.33%c |
a. Approved under the standard stated in the filing — “As a result, abstentions and "broker non-votes" (see below), if any, will not affect the outcome of the vote on this proposal.”.
b. Approved under the standard stated in the filing — “As a result, abstentions and "broker non-votes" (see below), if any, will not affect the outcome of the vote on this proposal.”.
c. Approved under the standard stated in the filing — “As a result, abstentions and "broker non-votes" (see below), if any, will not affect the outcome of the vote on this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Rachelle JacquesIndependent · Board Chair · Audit · Nominating/Governance | $72,582 | $35,616 | $107,584 | — | $0 | $215,782 |
| John JenkinsIndependent · Audit · Compensation (Chair) | 65,000 | 35,616 | 107,584 | — | 0 | 208,200 |
| Winston KungIndependent · Audit (Chair) | 60,000 | 35,616 | 107,584 | — | 0 | 203,200 |
| Alan HolmerIndependent · Departed during FY | 57,418 | 35,616 | 107,584 | — | 0 | 200,618 |
| Yong BenIndependent · Compensation · Nominating/Governance | 52,500 | 35,616 | 107,584 | — | 0 | 195,700 |
| Anne AltmeyerIndependent · Compensation · Nominating/Governance (Chair) | 50,646 | 35,616 | 107,584 | — | 0 | 193,846 |
| Peter SalzmannIndependent · Not standing for re-election · Departed during FY | 16,690 | — | — | — | 0 | 16,690 |
| Yuval CohenEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | — |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $374,836 |
| Equity awards (grant-date value) | $213,696 |
| All other compensation | $0 |
| Total cost of the board | $588,532 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Corbus Pharmaceuticals Holdings | 2025 | Yuval Cohen | $646,566 | $666,699 | $2,039,294 | $0 | $3,750,125 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Yuval Cohen | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Summary Compensation Table” · page 16. As printed: 3,750,125. Filing ↗machine: span 302905–302914 |
| 2 | Section 01, Dominic Smethurst | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Summary Compensation Table” · page 16. As printed: 1,800,142. Filing ↗machine: span 362871–362880 |
| 3 | Section 01, Sean Moran | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Summary Compensation Table” · page 16. As printed: 1,789,423. Filing ↗machine: span 332812–332821 |
| 4 | Section 03, Sean Moran Option | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t4 · r5 · c17 · span 328658–328665 |
| 5 | Section 03, Dominic Smethurst Option | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t4 · r8 · c17 · span 358717–358724 |
| 6 | Section 03, Yuval Cohen RSU | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t4 · r2 · c13 · span 297364–297371 |
| 7 | Section 03, Sean Moran RSU | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t4 · r5 · c13 · span 327273–327280 |
| 8 | Section 03, Yuval Cohen Option | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t4 · r2 · c17 · span 298749–298758 |
| 9 | Section 03, Dominic Smethurst RSU | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t4 · r8 · c13 · span 357332–357339 |
| 10 | Section 07, pay ratio | 10-K | 2026-03-09 | 0001193125-26-098530 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 11 | Section 08, Rachelle Jacques | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Director Compensation”. As printed: 215,782. Filing ↗machine: t14 · r3 · c14 · span 927958–928166 |
| 12 | Section 08, John Jenkins | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Director Compensation”. As printed: 208,200. Filing ↗machine: t14 · r4 · c14 · span 933923–934131 |
| 13 | Section 08, Winston Kung | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Director Compensation”. As printed: 203,200. Filing ↗machine: t14 · r8 · c14 · span 957120–957328 |
| 14 | Section 08, Alan Holmer | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Director Compensation”. As printed: 200,618. Filing ↗machine: t14 · r2 · c14 · span 922314–922522 |
| 15 | Section 08, Yong Ben | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Director Compensation”. As printed: 195,700. Filing ↗machine: t14 · r7 · c14 · span 951155–951363 |
| 16 | Section 08, Anne Altmeyer | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Director Compensation”. As printed: 193,846. Filing ↗machine: t14 · r6 · c14 · span 945519–945727 |
| 17 | Section 08, Peter Salzmann | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Director Compensation”. As printed: 16,690. Filing ↗machine: t14 · r5 · c3 · span 935784–935991 |
| 18 | Section 08, Yuval Cohen | DEF 14A | 2026-04-02 | 0001193125-26-140363 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 19 | Section 02, Brent Pfeiffenberger 2026-05-19 | Form 4 | 2026-05-21 | 0001193125-26-234813 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Anne Altmeyer 2026-05-19 | Form 4 | 2026-05-21 | 0001193125-26-234851 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, John Jenkins 2026-05-19 | Form 4 | 2026-05-21 | 0001193125-26-234853 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Rachelle Jacques 2026-05-19 | Form 4 | 2026-05-21 | 0001193125-26-234857 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Yong Ben 2026-05-19 | Form 4 | 2026-05-21 | 0001193125-26-234850 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Anne Altmeyer 2026-05-19 | Form 4 | 2026-05-21 | 0001193125-26-234851 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Brent Pfeiffenberger 2026-05-19 | Form 4 | 2026-05-21 | 0001193125-26-234813 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, John Jenkins 2026-05-19 | Form 4 | 2026-05-21 | 0001193125-26-234853 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Rachelle Jacques 2026-05-19 | Form 4 | 2026-05-21 | 0001193125-26-234857 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Yong Ben 2026-05-19 | Form 4 | 2026-05-21 | 0001193125-26-234850 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Winston Kung 2026-05-19 | Form 4 | 2026-05-21 | 0001193125-26-234860 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Winston Kung 2026-05-19 | Form 4 | 2026-05-21 | 0001193125-26-234860 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Nishant C. Saxena 2026-05-21 | Form 4 | 2026-05-22 | 0001193125-26-237103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Nishant C. Saxena 2026-05-21 | Form 4 | 2026-05-22 | 0001193125-26-237103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Nishant C. Saxena 2026-06-02 | Form 4 | 2026-06-03 | 0001193125-26-255834 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Nishant C. Saxena 2026-06-03 | Form 4 | 2026-06-03 | 0001193125-26-255834 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Winston Kung 2026-06-10 | Form 4 | 2026-06-11 | 0001193125-26-267672 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, John Jenkins 2026-06-10 | Form 4 | 2026-06-11 | 0001193125-26-267671 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Anne Altmeyer 2026-06-10 | Form 4 | 2026-06-11 | 0001193125-26-267655 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Yuval Cohen 2026-08-07 | Form 4 | 2026-08-10 | 0001193125-26-342485 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Sean Moran 2026-08-07 | Form 4 | 2026-08-10 | 0001193125-26-342479 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Nishant C. Saxena 2026-08-11 | Form 4 | 2026-08-12 | 0001193125-26-346966 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Leonardo Viana Nicacio 2026-08-16 | Form 4 | 2026-08-17 | 0001193125-26-354145 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Leonardo Viana Nicacio 2026-08-16 | Form 4 | 2026-08-17 | 0001193125-26-354145 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Yong Ben 2026-09-14 | Form 4 | 2026-09-15 | 0001193125-26-392093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 06, 2026 vote | Form 8-K | 2026-05-14 | 0001193125-26-222890 | Item 5.07 · say-on-pay result. As reported: 92.82% (votes for as printed: 9,325,932). Filing ↗ |
| 45 | Section 06, 2025 vote | Form 8-K | 2025-05-19 | 0000950170-25-073967 | Item 5.07 · say-on-pay result. As reported: 96.8% (votes for as printed: 6,519,904). Filing ↗ |
| 46 | Section 06, 2024 vote | Form 8-K | 2024-05-20 | 0000950170-24-062436 | Item 5.07 · say-on-pay result. As reported: 99.33% (votes for as printed: 6,593,949). Filing ↗ |
| 47 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 48 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 49 | Section 09b board cost (computed) | Computed | — | — | Cash 374,836 + equity 213,696 + all other 0 = 588,532, summed across the director compensation table rows.machine: formula: Σ = 588,532 |
| 50 | Corbus Pharmaceuticals Holdings (subject), Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140363 | CEO total compensation as printed in Corbus Pharmaceuticals Holdings's own proxy. As printed: 3,750,125. Filing ↗machine: span 302905–302914 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.